CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory MyelomaSimon J. Harrison, Piers Blombery, Cyrille Touzeau et al.|New England Journal of Medicine|2025Cited by 58
Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN StudyNirav N. Shah, Anthony R. Mato, Jennifer A. Woyach et al.|Blood|2022Cited by 4